<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9524">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982954</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-920</org_study_id>
    <nct_id>NCT02982954</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer</brief_title>
  <acronym>CHECKMATE 920</acronym>
  <official_title>Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with
      previously untreated advanced or metastatic Renal Cell Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of high grade immune-mediated adverse events (IMAEs)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>high grade IMAEs: Common Terminology Criteria for Adverse Events (CTCAE) version 4 Grade 3-4 and Grade 5 IMAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of all high grade IMAEs</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of all high grade IMAEs</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who received immune modulating medication due to high grade IMAEs</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at time of initial progression (PFS 1) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>ccRCC KPS ≥ 70%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ccRCC, KPS ≥ 70%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCC with non-active Brain Mets, KPS ≥70%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>any RCC with KPS 50%-60%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>ccRCC KPS ≥ 70%</arm_group_label>
    <arm_group_label>Non-ccRCC, KPS ≥ 70%</arm_group_label>
    <arm_group_label>RCC with non-active Brain Mets, KPS ≥70%</arm_group_label>
    <arm_group_label>any RCC with KPS 50%-60%</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified Dose on Specified Day</description>
    <arm_group_label>ccRCC KPS ≥ 70%</arm_group_label>
    <arm_group_label>Non-ccRCC, KPS ≥ 70%</arm_group_label>
    <arm_group_label>RCC with non-active Brain Mets, KPS ≥70%</arm_group_label>
    <arm_group_label>any RCC with KPS 50%-60%</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS-734016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

        1. Type of Participant and Target Disease Characteristics

          1. Advanced or metastatic RCC

          2. Histologically confirmed, previously untreated (treatment-naive) RCC

          3. No prior systemic therapy for RCC except for one prior adjuvant or neoadjuvant
             therapy for completely resectable RCC

          4. Measurable disease as per RECIST 1.1. Subject must have extracranial metastasis as
             measurable disease

          5. Karnofsky Performance Status (KPS) of at least 70% for Cohort 1, 2, and 3; KPS of
             50-60% for Cohort 4

          6. Tumor tissue need be received by the central vendor (block or unstained slides).
             Note: Fine Needle Aspiration (FNA)and bone metastases samples are not acceptable for
             submission.

        Exclusion Criteria:

          1. Medical Conditions

               1. Subjects with any active autoimmune disease or a history of known autoimmune
                  disease

               2. Prior malignancy active within the previous 3 years except for locally curable
                  cancers that have been apparently cured

               3. Known HIV or AIDS-related illness

               4. Any positive test for hepatitis B or hepatitis C virus indicating acute or
                  chronic infection.

          2. Prior/Concomitant Therapy

               1. Prior systemic treatment in the metastatic setting with Vascular epithelial
                  growth factor(VEGF) or VEGF receptor targeted therapy

               2. Prior treatment with an anti-Programmed Death (PD) -1, anti-PD-L1, anti-PD-L2,
                  anti-cluster of differentiation 137 (CD137), or anti-cytotoxic
                  T-lymphocyte-associated antigen 4(CTLA-4) antibody, or any other antibody or
                  drug specifically targeting T-cell co-stimulation or checkpoint pathways. This
                  includes the utilization of these agents in the neo-adjuvant or adjuvant
                  setting.

               3. Anti-cancer therapy less than 28 days prior to the first dose of study drug or
                  palliative, focal radiation therapy less than 14 days prior to the first dose of
                  study drug.

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwest Alabama Cancer Center, Pc</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemant Patel, Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alaska Urological Institute Dba Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Clark, Site 0038</last_name>
      <phone>907-276-1455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer And Research Centers, Pc</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Shtivelband, Site 0046</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group, P.A.</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Thaddeus Beck, Site 0028</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Central Coast Health Centers - San Luis Obispo Oncology And Hematology Health Center</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Dicarlo, Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Galamaga, Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology And Hematology Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Babu, Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arash Rezazadeh Kalebasty, Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samith Kochuparambil, Site 0009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hrom, Site 0045</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Treatment Center</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Sitki Copur, Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers Of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Goodman, Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Alter, Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Broome Oncology</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Harris, Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samer Kasbari, Site 0048</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists And Research Institute, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Olsen, Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates, Pa</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Lingerfelt, Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Mckean, Site 0036</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Yorio, Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hutson, Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Southwest Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Richey, Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Midland Allison Cancer Center</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Watkins, Site 0060</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Wilks, Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Research Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanny Aragon-Ching, Site 0042</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Mcfarlane, Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Chaudhry, Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Giever, Site 0016</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>December 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
